Brief: Candel Therapeutics Partners With The University Of Pennsylvania’S Center For Cellular Immunotherapies To Study Combinations Of Novel Viral Immunotherapy And Car-T Cell Therapy In Solid Tumor Models

Candel Therapeutics

26/10/2022 13:21

Oct 26 (Reuters) - Candel Therapeutics Inc  CADL.O :
    * CANDEL THERAPEUTICS PARTNERS WITH THE UNIVERSITY OF
PENNSYLVANIA’S CENTER FOR CELLULAR IMMUNOTHERAPIES TO STUDY
COMBINATIONS OF NOVEL VIRAL IMMUNOTHERAPY AND CAR-T CELL THERAPY
IN SOLID TUMOR MODELS
    * CANDEL THERAPEUTICS INC - GOAL OF EVALUATING COMBINATION
OF
NOVEL VIRAL IMMUNOTHERAPIES WITH AIM TO POTENTIATE CAR-T CELL
THERAPIES IN SOLID TUMORS
    * CANDEL-BOTH PARTIES RETAIN RIGHTS IN PROGRAMS & RIGHTS TO
PROCEED TOWARDS CLINICAL TRIALS TO STUDY COMBINATION THERAPIES
IN PATIENTS WITH SOLID TUMORS

Source text for Eikon:  ID:nGNXVCb0J 
Further company coverage:  CADL.O 
 ((Reuters.Briefs@thomsonreuters.com))